Search research articles
Contact Us
Filters
Showing results (71-80 of 102) with videos related to
Page
of 11
Sort By:
European Journal of Internal Medicine
|
December 25, 2021
Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study
Annelotte G C Broekhoven, Marta Fiocco, Dave Sprengers, et al.
United European Gastroenterology Journal
|
April 30, 2025
Rifaximin-α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization
Diederick J van Doorn, Kirsi M A van Eekhout, Koos de Wit, et al.
The Lancet. Gastroenterology & Hepatology
|
May 20, 2017
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial
Annikki de Niet, Louis Jansen, Femke Stelma, et al.
Liver Cancer
|
October 12, 2019
Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Tim A Labeur, Jeroen L A van Vugt, David W G Ten Cate, et al.
Journal of Hepatology
|
May 15, 2014
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels
Louis Jansen, Annikki de Niet, Femke Stelma, et al.
Antiviral Therapy
|
May 4, 2013
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir
R Bart Takkenberg, Louis Jansen, Annikki de Niet, et al.
Acta Oncologica (Stockholm, Sweden)
|
June 27, 2018
Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma
Tim A Labeur, David W G Ten Cate, R Bart Takkenberg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 25, 2025
The Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Change in Liver Stiffness in Patients With Chronic Hepatitis B
Lesley A Patmore, Kirsi van Eekhout, Özgür M Koc, et al.
Journal of Child and Adolescent Psychopharmacology
|
November 6, 2007
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
Thomas J Spencer, Christopher J Kratochvil, R Bart Sangal, et al.
Biological Psychiatry
|
December 21, 2014
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
W Joseph Herring, Kathryn M Connor, Neely Ivgy-May, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 102) with videos related to
Sort By:
Page
of 11
European Journal of Internal Medicine
|
December 25, 2021
Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study
Annelotte G C Broekhoven, Marta Fiocco, Dave Sprengers, et al.
United European Gastroenterology Journal
|
April 30, 2025
Rifaximin-α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization
Diederick J van Doorn, Kirsi M A van Eekhout, Koos de Wit, et al.
The Lancet. Gastroenterology & Hepatology
|
May 20, 2017
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial
Annikki de Niet, Louis Jansen, Femke Stelma, et al.
Liver Cancer
|
October 12, 2019
Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Tim A Labeur, Jeroen L A van Vugt, David W G Ten Cate, et al.
Journal of Hepatology
|
May 15, 2014
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels
Louis Jansen, Annikki de Niet, Femke Stelma, et al.
Antiviral Therapy
|
May 4, 2013
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir
R Bart Takkenberg, Louis Jansen, Annikki de Niet, et al.
Acta Oncologica (Stockholm, Sweden)
|
June 27, 2018
Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma
Tim A Labeur, David W G Ten Cate, R Bart Takkenberg, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 25, 2025
The Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Change in Liver Stiffness in Patients With Chronic Hepatitis B
Lesley A Patmore, Kirsi van Eekhout, Özgür M Koc, et al.
Journal of Child and Adolescent Psychopharmacology
|
November 6, 2007
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
Thomas J Spencer, Christopher J Kratochvil, R Bart Sangal, et al.
Biological Psychiatry
|
December 21, 2014
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
W Joseph Herring, Kathryn M Connor, Neely Ivgy-May, et al.
Page
of 11